{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:52:43Z","timestamp":1793465563991,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.annonc.2024.09.001","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T12:48:30Z","timestamp":1726318110000},"page":"31-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8396-9121","authenticated-orcid":false,"given":"H.","family":"Sakai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6260-6943","authenticated-orcid":false,"given":"J.","family":"Tsurutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0277-8196","authenticated-orcid":false,"given":"K.","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Aogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1907-0247","authenticated-orcid":false,"given":"K.","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4405-8231","authenticated-orcid":false,"given":"M.","family":"Tokiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tsuneizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2907-847X","authenticated-orcid":false,"given":"C.K.","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ezumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-5291","authenticated-orcid":false,"given":"T.","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.annonc.2024.09.001_bib1","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"issue":"17","key":"10.1016\/j.annonc.2024.09.001_bib2","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2024.09.001_bib3","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2024.09.001_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.annonc.2024.09.001_bib5","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2024.09.001_bib6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1470-2045(24)00128-1","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial","volume":"25","author":"Fehm","year":"2024","journal-title":"Lancet Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2024.09.001_bib7","article-title":"Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies","volume":"42","author":"Park","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2024.09.001_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101374","article-title":"185O Trastuzumab deruxtecan (T-DXd) vs treatment of physicians' choice (TPC) in patients (pts) with HER2-low unresectable and\/or metastatic breast cancer (mBC): a detailed safety analysis of the randomized, phase III DESTINY-Breast04 trial","volume":"8","author":"Rugo","year":"2023","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.annonc.2024.09.001_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00520-023-08220-5","article-title":"Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC\/ESMO consensus recommendation","volume":"32","author":"Jordan","year":"2023","journal-title":"Support Care Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2024.09.001_bib11","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s10147-024-02535-x","article-title":"2023 Japan Society of Clinical Oncology Clinical Practice Guidelines update for antiemesis","volume":"29","author":"Iihara","year":"2024","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2024.09.001_bib12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.annonc.2024.09.001_bib13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","article-title":"Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Hashimoto","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.09.001_bib14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejphar.2013.08.048","article-title":"Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting","volume":"722","author":"Navari","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.annonc.2024.09.001_bib15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2024.09.001_bib16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","article-title":"Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial","volume":"9","author":"Navari","year":"2011","journal-title":"J\u00a0Support Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2024.09.001_bib17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1634\/theoncologist.2017-0378","article-title":"Olanzapine-based triple regimens versus neurokinin-1 receptor antagonist-based triple regimens in preventing chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy: a network meta-analysis","volume":"23","author":"Zhang","year":"2018","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.annonc.2024.09.001_bib18","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00520-021-06606-x","article-title":"Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis","volume":"30","author":"Chow","year":"2022","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2024.09.001_bib19","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","article-title":"A\u00a0double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy","volume":"23","author":"Yanai","year":"2018","journal-title":"Int J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2024.09.001_bib20","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2024.09.001_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.annonc.2024.09.001_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-070304","article-title":"Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B)","volume":"13","author":"Sakai","year":"2023","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.annonc.2024.09.001_bib23","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1186\/s12885-021-08572-3","article-title":"Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials","volume":"21","author":"Yamamoto","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2024.09.001_bib24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00280-019-03868-5","article-title":"Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting","volume":"84","author":"Tanaka","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"10.1016\/j.annonc.2024.09.001_bib25","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/cam4.2979","volume":"9","author":"Matsumoto","year":"2020","journal-title":"Cancer Med"},{"issue":"9","key":"10.1016\/j.annonc.2024.09.001_bib26","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/annonc\/mdl137","article-title":"A\u00a0phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy","volume":"17","author":"Aapro","year":"2006","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2024.09.001_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41687-017-0022-5","article-title":"The Japanese version of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events","volume":"2","author":"Kawaguchi","year":"2017","journal-title":"J\u00a0Patient Rep Outcomes"},{"issue":"1","key":"10.1016\/j.annonc.2024.09.001_bib29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00520-016-3386-9","article-title":"Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study","volume":"25","author":"Mukhopadhyay","year":"2017","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2024.09.001_bib30","doi-asserted-by":"crossref","first-page":"372","DOI":"10.21037\/apm.2019.08.04","article-title":"A\u00a0randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide","volume":"8","author":"Tienchaiananda","year":"2019","journal-title":"Ann Palliat Med"},{"issue":"4","key":"10.1016\/j.annonc.2024.09.001_bib31","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.0006-341X.1999.01202.x","article-title":"Test-based exact confidence intervals for the difference of two binomial proportions","volume":"55","author":"Chan","year":"1999","journal-title":"Biometrics"},{"issue":"2","key":"10.1016\/j.annonc.2024.09.001_bib32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0885-3924(00)00159-7","article-title":"Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices","volume":"20","author":"Roscoe","year":"2000","journal-title":"J\u00a0Pain Symptom Manage"},{"issue":"1","key":"10.1016\/j.annonc.2024.09.001_bib33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/1756283X15618131","article-title":"Nausea: a review of pathophysiology and therapeutics","volume":"9","author":"Singh","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"issue":"1","key":"10.1016\/j.annonc.2024.09.001_bib34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00520-019-05012-8","article-title":"Revisiting the physiology of nausea and vomiting-challenging the paradigm","volume":"28","author":"Wickham","year":"2020","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2024.09.001_bib35","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/oncolo\/oyac240","article-title":"Duration of chemotherapy-induced nausea and vomiting (CINV) as a predictor of recurrent CINV in later cycles","volume":"28","author":"Navari","year":"2023","journal-title":"Oncologist"},{"issue":"14","key":"10.1016\/j.annonc.2024.09.001_bib36","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.22.01997","article-title":"Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer","volume":"41","author":"Sandhya","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.annonc.2024.09.001_bib37","first-page":"2644","article-title":"Doublet or triplet antiemetic prophylaxis for nausea and vomiting induced by trastuzumab deruxtecan: an open-label, randomized, and multicenter exploratory phase 2 study","volume":"14","author":"Iihara","year":"2023","journal-title":"J\u00a0Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2024.09.001_bib38","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(23)00628-9","volume":"25","author":"Bajpai","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424039954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424039954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T02:19:14Z","timestamp":1741918754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753424039954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0923753424039954"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2024.09.001","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2024.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}